**July 2022**

**APPLICATION FORM FOR COVID-19 VACCINE DELIVERY (CDS) - Third Funding Envelope of SUPPORT**

# Purpose of this document

This form must be completed to apply for CDS third Funding Envelope. Applicants are required to read the [COVID-19 Delivery Support (CDS) - Third Funding Window Guidelines](https://www.gavi.org/news/document-library/cds-needs-based-window-programme-funding-guidelines) prior to developing their requests and should submit their application form and associated attachments by email to covaxproposals@gavi.org. All Application documents are available on the[**COVAX website**](https://www.gavi.org/gavi-covax-amc#documents)**.**

**appendix of Application FORM**

Part A: Minister’s signatures

Part B: Checklist for mandatory attachments

Part C: Key application data and absorption of past CDS funds

Part D: Summary of Application, Technical Assistance & Financial Support

# Background

Since publication of the CDS Needs Based Window Programme Funding Guidelines in October 2021, the COVID-19 vaccine delivery environment has evolved. Notably, there has been increased supply of COVID-19 vaccines to the 92 AMC countries with subsequent increases in coverage in many countries, changes to WHO SAGE guidance, evolution of COVID-19 epidemiology, and additional funding available for Gavi to support country needs. Taking these into consideration, Gavi is making a new CDS funding envelope available. The envelope supports 3 core objectives:

1. Support acceleration of vaccination of **high & highest-risk populations** (as defined by SAGE)
2. Support rapid delivery scale-up to reach country targets for **adult vaccination**
3. Support **integration of C19 and routine immunisation** to achieve sustainable benefits

Countries can request funding up until **30th September 2022.** Countries are encouraged to use CDS funding through end of 2022, however, funding can be used until end 2023 given country priorities, in particular for activities related to integration.

#

# Part A: Ministers' signatures

|  |  |
| --- | --- |
| **Signatures** *We the undersigned, affirm the objectives and activities of the CDS support proposal are fully aligned with the national health strategic plan (or equivalent):* |  **Minister of Health (or delegated authority)** Name & Signature: Date:  |
| **Minister of Finance (or delegated authority)**  Name & Signature: Date:  |

# Part B: Mandatory attachments

All documents listed in the table below are mandatory, must be attached to your application, and they must be final and dated. Only complete applications will be assessed. *If countries conducted a COVID-19 Vaccination Intra-Action Review, or similar, please attach a copy of the report.*

| **No.** | **Strategy / Plan / Document** | **Attached****Yes/No** | **Final version (dated)** | **Comments** |
| --- | --- | --- | --- | --- |
| 1 | *CDS Funding Window Application form (including Signature sheet for the MoH or their delegated authority) – This document*  |  |  |  |
| 2 | Latest NDVP or other Plan of Action |  |  |  |
| 3 | Gavi Budget Template  |  |  |  |
| 4 | Minutes of the Coordination Forum meeting endorsing the proposal, or non-objection email  |  |  |  |

# Part C: Key application data and absorption of past CDS funds

|  |  |
| --- | --- |
| CDS - Third Funding Envelope (US$)*As communicated in July 2022* |  |
| Planned start and end date |  |

If you have had access to CDS funds in the past, please complete the following section:

|  |  |
| --- | --- |
| **Funding Window** | **% of Funds Absorption** |
| CDS Early Access |  |
| CDS Needs Based |  |
| Other |  |

# A picture containing background pattern  Description automatically generated

# Part D: Summary of the Application, Technical Assistance, and Financial Support

This section must be filled with appropriate reference to the Applicant documents listed in Part B.

**Summary of the request**

1. Provide a brief overview of the COVID-19 context in your country, including COVID-19 disease epidemiology and vaccination progress to-date.

ii) Please highlight key successes to the national COVID-19 vaccination delivery programme, as well as any on-going challenges and/or bottlenecks that are delaying or impeding achievement of the national coverage targets for COVID-19 vaccination delivery.

[If the above is addressed in your COVID-19 National Deployment and Vaccination Plan (NDVP), please indicate the relevant page(s) and provide only further updates to what has already been described since the NDVP was published.]

1. Provide in the table below the total budgeted amount per the 3 core CDS objectives and include a high level summary of the key activities requested to address the objectives. (*Please ensure the figures included in the table below are aligned to those reported in the budget template*).

|  |  |  |
| --- | --- | --- |
| **Core CDS Objectives** | **Summary of budget amount (US$)** | **High level summary of key activities** |
| 1. High risk population
 |  |  |
| 1. Adult Population
 |  |  |
| 1. C19 and RI integration
 |  |  |

1. Describe how CDS funding will support acceleration of vaccination of **high & highest-risk populations** (as defined by SAGE). Please include details on the populations to be targeted and how the key activities planned will address the challenges/bottlenecks to vaccine-scale up that have been encountered to date.
2. Describe the key activities necessary to achieve the national **adult vaccination** targets. This should includereferences to needs identified in the NDVP. Where relevant, please also provide details on how CDS funding will continue to support the following;
* Vaccine delivery strategy / reaching vulnerable and marginalised populations
* Vaccine safety monitoring and management of AEFI
* Supply chain and waste management support
* Data collection, evaluation and reporting practices
* Innovation



1. Complete the table below to confirm your coverage targets related to both high & highest risk populations and adult population. Please complete targets with **both** numerical values and % targets. *We encourage you to align with any coverage targets already formally communicated (for example through the COVAX Demand Planning Exercise coordinated by CoVDP and Gavi), or alternatively, flag justification for any divergence from any targets already communicated.*

|  |  |  |  |
| --- | --- | --- | --- |
|  | Actuals at time of application (baseline) | Targets for end of 2022 | Targets for end of 2023 |
| High and highest risk populations | **Complete Primary Series** | Coverage of older adult\* population [Number & %] |  |  |  |
| Coverage of health care workers[Number & %] |  |  |  |
| Coverage of *other target group/s (please specify)* |  |  |  |
| **With booster/s** | Coverage of older adult population [Number & %] |  |  |  |
| Coverage of health care workers[Number & %] |  |  |  |
| Coverage of *other target group/s (please specify)* |  |  |  |
|  | **Actuals at time of application (baseline)** | **Targets for end of 2022** | **Targets for end of 2023** |
| Adult population | **Complete Primary Series** | Coverage of total adult population [Number & %] |  |  |  |
| **With booster/s** | Coverage of total adult population [Number & %] |  |  |  |

*\*Per WHO SAGE Roadmap, the threshold for the definition of “older adults” may vary from country to country but is typically adults older than 60 years of age.*

1. Describe how CDS funding will support **integration of C19 with routine immunisation** services.



**Technical assistance (TA)**

An overview of your TA needs, proposed activities, budget and potential providers should be reflected in the **TA tab** within the Gavi Budget Template.

Following completion of the CDS TA tab, please summarise the TA requested in the Table below.

The Table gives an overview of the total amount requested for TA broken down by fund recipients and partner category (Core/Global Expanded/ Local Expanded Partners).

For the purposes of CDS, Technical Assistance (TA) refers to activities planned by partners (not MOH) corresponding to the Human Resources costs as per Annex 2 in the CDS guidance (Cost inputs 1.1, 1.2, 1.3, 1.4, 2.5 and 5.1) only. All activities not meeting this description should NOT be included in the TA tabs or summary table below.

The total amount for TA should be included as a line item in the CDS country budget per partner.

*TA Summary Table*

|  |  |  |  |
| --- | --- | --- | --- |
| *Partner Category[[1]](#footnote-2)* | *Fund recipient[[2]](#footnote-3)*  | *Number of staff/consultant positions planned to be funded (FTE)* | *TA Funding amount (US$)**(Inclusive of PSC for TA)* |
|  |   |  |   |
|  |   |  |   |
|  |   |  |   |
|  |  | Total TA Funding amount (US$) |  |

**Financial support:**

1. If you have previously accessed CDS funding through the Early Access Funds or Needs Based window, please describe:
	1. the fund utilization to date including any commitments,
	2. forecasted expenditure for the remainder of those funds,
	3. anticipated date that additional funding support will be needed to ensure vaccine implementation is not interrupted?
1. Partner Category includes Core Partners (WHO/UNICEF/ CDC/ WB), Global Expanded Partners and Local Expanded Partners (HQ in country of implementation). [↑](#footnote-ref-2)
2. Name of organisation selected. [↑](#footnote-ref-3)